Developer docs
API playgroundTry for free, no card

Search company profiles

108 BioCapital

Full company profile

uuid00sagt7

Namestring
108 BioCapital
Legal namestring
108 BioCapital Growth Stage Fund
Websiteurl
108.bio
Company typeenum
Private
Founded yearstring
-
Descriptiontext

108 BioCapital is a US-based private equity growth-stage fund that invests in innovative biotech and medtech companies developing transformative healthcare solutions. The fund, operating under the legal name 108 BioCapital Growth Stage Fund, is led by Founder & CEO Dr. Sasha Bakhru, a biotechnologist and entrepreneur who is the inventor or co-inventor of drug discoveries including Ciraparantag and Amylyx, both of which were successfully commercialized. The fund targets growth-stage companies addressing significant unmet medical needs, with the underlying market thesis citing US healthcare spending projected to reach 20% of GDP by 2032.

The fund's business model is a traditional private equity growth-equity structure: it raises capital from accredited investors through a private placement memorandum and deploys that capital into portfolio companies, generating revenue through management fees and future carried interest upon successful exits. As of February 2026, the fund had achieved a first close of over $40 million and made its inaugural investment of $20 million in Pinwheel Therapeutics to fund Phase 2b clinical trials of Ciraparantag, a next-generation universal anticoagulant reversal agent positioned to address a market gap following the withdrawal of Andexxa from the US market in December 2025. The fund is backed by Ranjan Pai and has initiated registration for a Gift City feeder vehicle to access international limited partners.

The fund's competitive positioning rests on its leadership team's combined scientific, operational, and investment expertise, supported by a senior advisory bench spanning regulatory affairs, intellectual property law, biopharma commercialization, and legal structuring. The team operates with a small core staff (1–10 employees) augmented by advisors with backgrounds at Johnson & Johnson, Bristol-Myers Squibb, Pfizer, and other major healthcare organizations, providing portfolio companies with regulatory, clinical, and go-to-market guidance alongside growth capital.

Short descriptiontext

108 BioCapital is a US-based private equity growth-stage fund investing in biotech and medtech companies addressing unmet medical needs. Led by Dr. Sasha Bakhru, the fund provides growth capital and operational expertise to innovative healthcare companies, having closed over $40M at first close in February 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
biotech private equity, medtech growth capital, healthcare venture investing, biopharma growth equity, life sciences investment
Industry2 codes
PRIMARYHLAAAFAC
Consortia & Defined Microbial Community Therapeutics
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Security Brokers, Dealers & Flotation Companies6211
  • Services-Commercial Physical & Biological Research8731
Product category
Healthcare Private Equity
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

108 BioCapital is a US-based private equity fund that provides growth-stage capital to innovative biotech and medtech companies addressing significant unmet medical needs. The fund combines deep scientific expertise with investment acumen to identify, nurture, and scale high-potential healthcare opportunities, with its inaugural $20 million commitment to Pinwheel Therapeutics supporting Phase 2b clinical trials for Ciraparantag, a universal anticoagulant reversal agent.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

108 BioCapital operates as a single private equity fund focused on biotech and medtech investments. The fund targets innovative companies addressing urgent unmet medical needs, combining deep scientific expertise with investment acumen to identify and scale high-potential opportunities. The company was founded by Dr. Sasha Bakhru, who previously invented or co-invented drug discoveries including Ciraparantag and Amylyx, both successfully commercialized, and created the first PoC Coagulometer for anticoagulant therapy monitoring.

Product and service1 record
1108 BioCapital Growth Stage Fund
CategoryPrivate Equity Fund
Description

A US-based private equity fund that invests growth-stage capital in innovative biotech and medtech companies addressing significant unmet medical needs; offered exclusively to accredited investors via private placement memorandum.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

RA Capital is a healthcare-focused crossover fund manager investing in publicly and privately held biotech and medical device companies. Its growth-stage biotech investing model is closely comparable to 108 BioCapital's mandate.

TypeRegional player
Description

Sofinnova Partners is a European venture capital firm dedicated to life sciences including biotech and medtech. Its specialist life sciences focus parallels 108 BioCapital's mandate, though it primarily operates in Europe rather than the US.

TypeDirect peer
Description

ARCH Venture Partners is a leading biotech-focused venture capital firm investing in early-stage and growth-stage life sciences companies. Its scientific-founder orientation and biotech-only focus mirror 108 BioCapital's approach.

4Baker Bros. Advisors
TypeDirect peer
Description

Baker Bros. Advisors is a dedicated biotech-focused long-only manager investing across stages in life sciences companies. Its biotech-only mandate and scientific-analyst-led approach parallels 108 BioCapital's thesis.

TypeDirect peer
Description

5AM Ventures is an early-stage life sciences venture capital firm investing in biotech companies. Its specialist life sciences mandate and stage overlap makes it a relevant comparable to 108 BioCapital.

TypeDirect peer
Description

Atlas Venture is a life sciences-focused venture capital firm building and funding biotech companies from inception through clinical development. Its specialist biotech focus parallels 108 BioCapital's mandate and stage.

TypeBroad incumbent
Description

NEA is a large multi-stage venture capital firm with a dedicated healthcare practice investing across biotech, medical devices, and digital health. While broader than 108 BioCapital, its healthcare growth-stage practice is comparable.

TypeDirect peer
Description

Frazier Healthcare Partners is a dedicated healthcare PE/VC firm investing across therapeutics, medical devices, and biotech at multiple stages. Its healthcare-only focus and growth-stage fund structure make it a direct peer.

TypeDirect peer
Description

OrbiMed is one of the largest dedicated healthcare-focused investment firms globally, investing across biopharma, medical devices, and diagnostics at all stages. Its healthcare-only mandate and growth-equity emphasis directly parallels 108 BioCapital's focus.

TypeDirect peer
Description

Perceptive Advisors is a healthcare-focused investment firm managing credit and equity strategies in biotech and medical devices. Its growth-stage healthcare investing and willingness to back clinical assets is highly comparable to 108 BioCapital.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

108 BioCapital

Healthcare Private Equity108.bio

108 BioCapital is a US-based private equity growth-stage fund investing in biotech and medtech companies addressing unmet medical needs. Led by Dr. Sasha Bakhru, the fund provides growth capital and operational expertise to innovative healthcare companies, having closed over $40M at first close in February 2026.

What 108 BioCapital does

108 BioCapital is a US-based private equity growth-stage fund that invests in innovative biotech and medtech companies developing transformative healthcare solutions. The fund, operating under the legal name 108 BioCapital Growth Stage Fund, is led by Founder & CEO Dr. Sasha Bakhru, a biotechnologist and entrepreneur who is the inventor or co-inventor of drug discoveries including Ciraparantag and Amylyx, both of which were successfully commercialized. The fund targets growth-stage companies addressing significant unmet medical needs, with the underlying market thesis citing US healthcare spending projected to reach 20% of GDP by 2032.

The fund's business model is a traditional private equity growth-equity structure: it raises capital from accredited investors through a private placement memorandum and deploys that capital into portfolio companies, generating revenue through management fees and future carried interest upon successful exits. As of February 2026, the fund had achieved a first close of over $40 million and made its inaugural investment of $20 million in Pinwheel Therapeutics to fund Phase 2b clinical trials of Ciraparantag, a next-generation universal anticoagulant reversal agent positioned to address a market gap following the withdrawal of Andexxa from the US market in December 2025. The fund is backed by Ranjan Pai and has initiated registration for a Gift City feeder vehicle to access international limited partners.

The fund's competitive positioning rests on its leadership team's combined scientific, operational, and investment expertise, supported by a senior advisory bench spanning regulatory affairs, intellectual property law, biopharma commercialization, and legal structuring. The team operates with a small core staff (1–10 employees) augmented by advisors with backgrounds at Johnson & Johnson, Bristol-Myers Squibb, Pfizer, and other major healthcare organizations, providing portfolio companies with regulatory, clinical, and go-to-market guidance alongside growth capital.

108 BioCapital firmographics

Firmographics
Name
108 BioCapital
Legal name
108 BioCapital Growth Stage Fund
Website
https://108.bio
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
108 BioCapital is a US-based private equity growth-stage fund investing in biotech and medtech companies addressing unmet medical needs. Led by Dr. Sasha Bakhru, the fund provides growth capital and operational expertise to innovative healthcare companies, having closed over $40M at first close in February 2026.
Ownership category
akta.pro rank

108 BioCapital industry classification

Industry
Product category
Healthcare Private Equity
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Security Brokers, Dealers & Flotation Companies (6211), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAC
Consortia & Defined Microbial Community Therapeutics
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Biotech private equity
  • Medtech growth capital
  • Healthcare venture investing
  • Biopharma growth equity
  • Life sciences investment

108 BioCapital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

108 BioCapital product offering

Product offering

Core offering

108 BioCapital is a US-based private equity fund that provides growth-stage capital to innovative biotech and medtech companies addressing significant unmet medical needs. The fund combines deep scientific expertise with investment acumen to identify, nurture, and scale high-potential healthcare opportunities, with its inaugural $20 million commitment to Pinwheel Therapeutics supporting Phase 2b clinical trials for Ciraparantag, a universal anticoagulant reversal agent.

Product overview

108 BioCapital operates as a single private equity fund focused on biotech and medtech investments. The fund targets innovative companies addressing urgent unmet medical needs, combining deep scientific expertise with investment acumen to identify and scale high-potential opportunities. The company was founded by Dr. Sasha Bakhru, who previously invented or co-invented drug discoveries including Ciraparantag and Amylyx, both successfully commercialized, and created the first PoC Coagulometer for anticoagulant therapy monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

  • 108 BioCapital Growth Stage Fund A US-based private equity fund that invests growth-stage capital in innovative biotech and medtech companies addressing significant unmet medical needs; offered exclusively to accredited investors via private placement memorandum.

Companies that use 108 BioCapital

Customer profile

Segments1 record

Ideal customer profiles2 records

108 BioCapital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

108 BioCapital partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

108 BioCapital competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: RA Capital is a healthcare-focused crossover fund manager investing in publicly and privately held biotech and medical device companies. Its growth-stage biotech investing model is closely comparable to 108 BioCapital's mandate.
  • ARCH Venture Partners: ARCH Venture Partners is a leading biotech-focused venture capital firm investing in early-stage and growth-stage life sciences companies. Its scientific-founder orientation and biotech-only focus mirror 108 BioCapital's approach.
  • Baker Bros. Advisors: Baker Bros. Advisors is a dedicated biotech-focused long-only manager investing across stages in life sciences companies. Its biotech-only mandate and scientific-analyst-led approach parallels 108 BioCapital's thesis.
  • 5AM Ventures: 5AM Ventures is an early-stage life sciences venture capital firm investing in biotech companies. Its specialist life sciences mandate and stage overlap makes it a relevant comparable to 108 BioCapital.
  • Atlas Venture: Atlas Venture is a life sciences-focused venture capital firm building and funding biotech companies from inception through clinical development. Its specialist biotech focus parallels 108 BioCapital's mandate and stage.
  • Frazier Healthcare Partners: Frazier Healthcare Partners is a dedicated healthcare PE/VC firm investing across therapeutics, medical devices, and biotech at multiple stages. Its healthcare-only focus and growth-stage fund structure make it a direct peer.
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare-focused investment firms globally, investing across biopharma, medical devices, and diagnostics at all stages. Its healthcare-only mandate and growth-equity emphasis directly parallels 108 BioCapital's focus.
  • Perceptive Advisors: Perceptive Advisors is a healthcare-focused investment firm managing credit and equity strategies in biotech and medical devices. Its growth-stage healthcare investing and willingness to back clinical assets is highly comparable to 108 BioCapital.

Regional players

  • Sofinnova Partners: Sofinnova Partners is a European venture capital firm dedicated to life sciences including biotech and medtech. Its specialist life sciences focus parallels 108 BioCapital's mandate, though it primarily operates in Europe rather than the US.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a large multi-stage venture capital firm with a dedicated healthcare practice investing across biotech, medical devices, and digital health. While broader than 108 BioCapital, its healthcare growth-stage practice is comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

108 BioCapital social profiles

Digital presence

108 BioCapital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

108 BioCapital leadership team

Management profile

Number of profiles

Profiles11 records

108 BioCapital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

108 BioCapital M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 108 BioCapital

What does 108 BioCapital do?

108 BioCapital is a US-based private equity fund that provides growth-stage capital to innovative biotech and medtech companies addressing significant unmet medical needs. The fund combines deep scientific expertise with investment acumen to identify, nurture, and scale high-potential healthcare opportunities, with its inaugural $20 million commitment to Pinwheel Therapeutics supporting Phase 2b clinical trials for Ciraparantag, a universal anticoagulant reversal agent.

Is 108 BioCapital a public or private company?

108 BioCapital is a private company. It is classified as venture growth investor backed and is currently operating.

When was 108 BioCapital founded?

108 BioCapital was founded in -1. It employs 1 to 10 people.

Who are 108 BioCapital's main competitors?

Direct peers on record are RA Capital Management, ARCH Venture Partners, Baker Bros. Advisors, 5AM Ventures, Atlas Venture, Frazier Healthcare Partners, OrbiMed and Perceptive Advisors. Sofinnova Partners is listed as a regional player. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does 108 BioCapital have an API?

No public API is recorded for 108 BioCapital.

What industry is 108 BioCapital in?

108 BioCapital's product category is Healthcare Private Equity. Its primary akta.pro industry code is HLAAAFAC, Consortia & Defined Microbial Community Therapeutics, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 541714 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0CellsBin Raises Series A Led By 108 BioCapital To Advance Rare-Cell Intelligence PlatformCellsBin closed a Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence platform, which combines microfluidics, imaging, single-cell analysis, and AI to detect rare cells. The company did not disclose the amount raised. Proceeds will support commercial adoption, partnerships, and research.VC News DailySedMed Attains $4M Funding108 BioCapital announced a $4 million investment in SedMed, Inc., leading a financing round. The funds will support commercial expansion, distribution partnerships, intellectual property, and hospital-based studies for SedMed's non-electric toilet lift.FinSMEsSedMed Raises $4M in FundingSedMed, a Milford, CT-based medtech company, raised $4M in funding led by 108 BioCapital. The company will use the funds to accelerate commercial expansion, grow distribution and channel partnerships, advance its intellectual property portfolio, and conduct additional hospital-based studies. SedMed serves over 40 hospital systems.Yahoo108 BioCapital Leads SedMed, Inc. Financing with $4 Million Investment108 BioCapital led a $4 million financing round for SedMed, Inc., a medical device company developing non-electric toilet lifts. The funds will support commercial expansion, distribution, and hospital-based studies. The company cites adoption across over 40 hospital systems and sees international opportunity.PR Newswire108 BioCapital Leads SedMed, Inc. Financing with $4 Million Investment108 BioCapital led a $4 million financing round for SedMed, Inc., a medical device company developing non-electric toilet lifts. The funds will support commercial expansion, distribution, and hospital-based studies, with adoption across over 40 hospital systems. The company sees potential in international markets like India.BioSpaceCellsBin® Closes Series A Financing Led by 108 BioCapital to Advance Its Rare-Cell Intelligence™ PlatformCellsBin closed Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence platform. The company will use proceeds to accelerate commercialization, partnerships, and product development. Applications focus on cell and gene therapy monitoring and hematologic cancers.PR NewswireCellsBin® Closes Series A Financing Led by 108 BioCapital to Advance Its Rare-Cell Intelligence™ PlatformCellsBin closed its Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence platform. The company will use the proceeds to accelerate commercialization, partnerships, and product development. The platform targets cell and gene therapy monitoring and hematologic cancers.FinSMEsCellsBin Closes Series A FinancingCellsBin, a Brandford, Conn.-based biotechnology company, closed its Series A financing led by 108 BioCapital. The company will use the funds to accelerate commercialization, strategic partnerships, product development, and expansion of its clinical and technical capabilities. Its Rare-Cell Intelligence platform integrates microfluidics, imaging, single-cell analysis, and AI to detect rare cells.Express PharmaPinwheel Therapeutics raises $20mn from 108 BioCapitalPinwheel Therapeutics raised $20 million from 108 BioCapital for its late-stage clinical asset Ciraparantag, a universal anticoagulant reversal therapy. The fund's first close exceeded $40 million, and the investment targets the $1.4 billion global anticoagulant reversal market.BW Healthcare World108 BioCapital Backs Pinwheel Therapeutics With $20 Mn For Ciraparantag TrialUS-based biotech private equity fund 108 BioCapital has made its inaugural investment by committing $20 million to Pinwheel Therapeutics to support the Phase 2b clinical trial of Ciraparantag, a next-generation universal anticoagulant reversal agent being developed for emergency settings. Ciraparantag is positioned to address a critical market gap following the withdrawal of Andexxa from the US market in December 2025, with worldwide patent protection extending until at least Q1 2034. The global anticoagulant reversal market is estimated at approximately $1.4 billion, with the therapy targeting the most prescribed anticoagulants including Eliquis, Xarelto, and Pradaxa.